X
[{"orgOrder":0,"company":"Medivir","sponsor":"Shijiazhuang Yuanmai Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear\u00ae in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Medivir"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sobi To Streamline Nirsevimab Contractual Arrangements","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Large molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Swedish Orphan Biovitrum AB"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The termination removes Sobi's right to AstraZeneca's full share of US profits and losses for Beyfortus (nirsevimab), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody, including US development and commercialisation costs.
Lead Product(s):
Nirsevimab
Therapeutic Area: Infections and Infectious Diseases
Product Name: Beyfortus
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Sanofi
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
April 09, 2023
Details:
The agreement gives SYB the right to register, manufacture and market the product in China.
Lead Product(s):
Aciclovir ,Hydrocortisone
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Shijiazhuang Yuanmai Biotechnology
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
February 24, 2020